{"schema_version":"secwatch.filing_event.v1","accession":"0001759138-26-000010","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.095654+00:00","generated_at":"2026-05-15T09:23:01.328982+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cabaletta Bio Q4/FY2025 cash $133.6M; myositis BLA on track for 2027; $30M raise","bullets":["Q4 R&D expenses $36.2M, FY R&D $142.7M; cash $133.6M as of Dec 31, 2025; raised additional $30M in Q1 2026.","Registrational DM/ASyS cohort enrolling (17 patients); BLA submission for rese-cel in myositis targeted for 2027.","No-preconditioning rese-cel data from RESET-SLE expected 1H26 (initial) and 2H26 (durability); PV durability data throughout 2026.","Automated manufacturing with Cellares: initial clinical data expected 1H26; potential to produce for thousands per year.","Complete Phase 1/2 data from RESET-SSc, RESET-SLE, RESET-MG to be presented in 1H26; design updates for SSc in 1H26 and MG mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001759138-26-000010","json":"https://secwatch.observer/filing/0001759138-26-000010.json","markdown":"https://secwatch.observer/filing/0001759138-26-000010.md","text":"https://secwatch.observer/filing/0001759138-26-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000010/0001759138-26-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000010/caba-20260323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:23:01.328982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6dc9f71dfc5d56e07ee5cbe72e04a8efd200a768","claim":"Cabaletta Bio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"On March 23, 2026, Cabaletta Bio, Inc. (the \"Company\") announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000175913826000010/0001759138-26-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}